ChemeBio (300122.SZ): Application for clinical trials of herpes zoster mRNA vaccine accepted

Zhtng Cijng APP News, Zh fi shngw (300122.SZ) released an announcement stating that the company recently learned that the herpes zoster mRNA vaccine developed by its wholly-owned subsidiary, Anhui Zhfi Lngkm Shngw Zhyo Yuxin Gngs (referred to as "Zhfi Lngkm"), has received a notice of acceptance for drug clinical trial application from the National Medical Products Administration (acceptance number: CXSL2500961). If within 60 days from the date of acceptance, no denial or objections are received from the drug review center, Zhfi Lngkm can proceed with the clinical trials as per the submitted plan. The herpes zoster mRNA vaccine developed by Zhfi Lngkm is used for preventing diseases caused by herpes zoster infection.